Literature DB >> 3746633

Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve.

B Hecquet, M Sucche.   

Abstract

A mathematical model for area under the curve (AUC) determination is proposed taking into account the circadian variation of cisplatin protein binding. The main theoretical result obtained with the model is that early morning drug administration (2-4 AM) promotes the highest AUC. The model predicts a maximum AUC variation, due to the binding variation, ranging between 2.4 and 15%. The minimum of AUC between 2.45 and 3.30 PM is in agreement with the minimum nephrotoxicity observed when cisplatin is injected in the afternoon. The model can be applied to other drugs that are irreversively bound to proteins or irreversively bound to other plasma components if the binding rate depends on the time of day. The variation intensity of AUC was demonstrated to depend on drug characteristics, but can never be higher than the circadian variation of the protein binding rate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3746633     DOI: 10.1007/bf01059285

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  Effects of "jet lag" on hormonal patterns. I. Procedures, variations in total plasma proteins, and disruption of adrenocorticotropin-cortisol periodicity.

Authors:  D Désir; E Van Cauter; V S Fang; E Martino; C Jadot; J P Spire; P Noël; S Refetoff; G Copinschi; J Golstein
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

Review 2.  Plasma protein binding and therapeutic drug monitoring.

Authors:  M Rowland
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

3.  [Circadian and circannual rhythms in the blood (leucocytes, total proteins, IgA, IgG and IgM) of young healthy adults (author's transl)].

Authors:  A Reinberg; E Schuller; N Delasnerie; J Clench; M Helary
Journal:  Nouv Presse Med       Date:  1977-12-03

Review 4.  Cisplatin: impact of a new anticancer agent on current therapeutic strategies.

Authors:  M Rozencweig; R Abele; D D von Hoff; F M Muggia
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

5.  Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing.

Authors:  F A Levi; W J Hrushesky; C H Blomquist; D J Lakatua; E Haus; F Halberg; B J Kennedy
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

6.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration.

Authors:  F A Levi; W J Hrushesky; F Halberg; T R Langevin; E Haus; B J Kennedy
Journal:  Eur J Cancer Clin Oncol       Date:  1982-05

8.  Mechanism of cisplatin nephrotoxicity.

Authors:  M W Weiner; C Jacobs
Journal:  Fed Proc       Date:  1983-10

9.  Time dependency in plasmatic protein binding of cisplatin.

Authors:  B Hecquet; J Meynadier; J Bonneterre; L Adenis; A Demaille
Journal:  Cancer Treat Rep       Date:  1985-01

10.  Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism.

Authors:  F Levi; W J Hrushesky; R F Borch; M E Pleasants; B J Kennedy; F Halberg
Journal:  Cancer Treat Rep       Date:  1982-11
View more
  2 in total

Review 1.  Chronopharmacokinetics. Current status.

Authors:  B Bruguerolle
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

2.  Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.

Authors:  Khalid O Alfarouk; Christian-Martin Stock; Sophie Taylor; Megan Walsh; Abdel Khalig Muddathir; Daniel Verduzco; Adil H H Bashir; Osama Y Mohammed; Gamal O Elhassan; Salvador Harguindey; Stephan J Reshkin; Muntaser E Ibrahim; Cyril Rauch
Journal:  Cancer Cell Int       Date:  2015-07-15       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.